Cytovale, a medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, has named Robert Scoggins, M.D., Ph.D., a seasoned ICU and critical care executive, as its first-ever chief medical officer (CMO).
In this role, Dr. Scoggins will be responsible for overseeing the company’s direction regarding clinical operation strategies. Driven by a desire to represent patient voices and the healthcare community and equipped with a background in clinical medicine, hospital operations and science, Dr. Scoggins will identify and address key issues currently within hospital settings through the development and commercialization of novel technologies.
“As Cytovale’s CMO, I am excited to be working alongside the leadership team to further the company’s commitment in solving health challenges by powering early detection technologies,” said Dr. Scoggins. “I’m joining at a pivotal time for the company, as we ramp up commercialization efforts for the FDA cleared IntelliSep test, Cytovale’s flagship diagnostic tool. I am excited to play a role in bringing the diagnostic to market as I, a pulmonary and critical care physician, have a deep understanding of the challenges hospital systems face and the urgent need they have for tools like IntelliSep.”
IntelliSep is a groundbreaking diagnostic tool that received FDA 510(k) clearance in December 2022 to aid in the early detection of sepsis, supporting critical time-sensitive clinical decisions in the emergency department through its efficient 10-minute testing period. Sepsis is the leading cause of death worldwide and is responsible for more than 350,000 deaths every year in the United States—more than opioid overdoses, prostate cancer, and breast cancer combined. 1,2 According to the Sepsis Alliance, as many as 80 percent of sepsis deaths could be prevented with rapid diagnosis and treatment—making early detection critical to improving clinical, operational, and financial outcomes. 1
Dr. Scoggins has previously held a breadth of leadership positions within hospitals, including Chief of Staff and ICU Medical Director, and chaired several hospital operational and medical staff committees including Sepsis, Pharmacy and Therapeutics and Multispecialty Peer Review. He began his career in science with an undergraduate degree in Molecular Biology from Vanderbilt University and obtained a PhD in Microbiology at the University of Virginia as part of a combined MD, PhD program. He completed his residency in Internal Medicine and fellowship in Pulmonary and Critical Care at Vanderbilt University.
About Cytovale®
Cytovale is committed to improving human health by pioneering early detection technologies powered by insightful assessment of immune activation. Made up of an extraordinary team of life scientists, engineers, clinicians, and dreamers, Cytovale intends to accelerate the time it takes to get from triage to life-saving therapies. For more information, please visit www.cytovale.com. For updates, follow Cytovale on LinkedIn and Twitter.
This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; the Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50119C00072.
References:
1. What Is Sepsis?, Sepsis Alliance (2022)
2. Sepsis Awareness Study Summary Report, Radius Global Market Research (2019).
The Editorial Team at Healthcare Business Today is made up of skilled healthcare writers and experts, led by our managing editor, Daniel Casciato, who has over 25 years of experience in healthcare writing. Since 1998, we have produced compelling and informative content for numerous publications, establishing ourselves as a trusted resource for health and wellness information. We offer readers access to fresh health, medicine, science, and technology developments and the latest in patient news, emphasizing how these developments affect our lives.
